SML0178

ARL-17477 dihydrochloride hydrate

≥98% (HPLC)

• Sinónimos: N-[4-[2-[[(3-chlorophenyl)methyl]amino]ethyl]phenyl]-2-thiophenecarboximidamide dihydrochloride hydrate
• Fórmula empírica (notación de Hill): C₂₀H₂₀ClN₃S·2HCl · xH₂O
• Número CAS: 866914-87-6
• Peso molecular: 442.83 (anhydrous basis)
• NACRES: NA.77
• PubChem Substance ID: 329825207
• UNSPSC Code: 12352202
• MDL number: MFCD21608518
• Assay: ≥98% (HPLC)
• Form: powder
• Storage condition: desiccated

Propiedades

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• storage condition: desiccated
• color: white to beige
• solubility: H₂O: ≥5 mg/mL
• originator: AstraZeneca
• storage temp.: 2-8°C
• SMILES string: O.Cl.Cl.Clc1cccc(CNCCc2ccc(NC(=N)c3cccs3)cc2)c1
• InChI: 1S/C20H20ClN3S.2ClH.H2O/c21-17-4-1-3-16(13-17)14-23-11-10-15-6-8-18(9-7-15)24-20(22)19-5-2-12-25-19;;;/h1-9,12-13,23H,10-11,14H2,(H2,22,24);2*1H;1H2
• InChI key: QOPATWWWZNTSQF-UHFFFAOYSA-N

Descripción

Application

ARL-17477 dihydrochloride hydrate may be used in cell signaling studies.

Biochem/physiol Actions

ARL-17477 dihydrochloride hydrate is a selective nNOS inhibitor

ARL-17477 is an nNOS specific inhibitor. The IC₅₀ against rat nNOS is 35 nM and it has 100-fold selectivity over endothelial and inducible isoforms. ARL-17477 penetrates the brain, and reduces infarct size and reduces cerebral blood flow in several different rodent models of ischemic brain injury.

Features and Benefits

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Pictogramas: GHS07
• Palabra de advertencia: Warning
• Códigos de peligro: H302,H319
• Indicaciones de precaución: P264 - P280 - P301 + P312 - P305 + P351 + P338 - P337 + P313 - P501
• Hazard Classifications: Acute Tox. 4 Oral - Eye Irrit. 2
• Clase de almacenamiento: 11 - Combustible Solids
• ¿Qué está pasando?: WGK 3
• Punto de inflamación (°F): Not applicable
• Punto de inflamación (°C): Not applicable